Abstract:ERAP1 is an enzyme that plays a key role in the antigen processing and presentation pathway as an editor of the peptide repertoire, allowing for the binding of neoantigens to MHC I. ERAP1 is polymorphic, with the different allelic variants showing various degrees of peptide trimming function expressed in humans. However, the trimming mechanism by which ERAP1 trims peptides is still not fully understood. The purpose of the study is to characterize the effect of the different ERAP1 variants and their inhibition on the peptide repertoire presented by tumor cells, enabling us to gain valuable insights into how this process works. This characterization will also enhance the pharmacological modulation of ERAP1, which has already been proven to promote T cell and NK-mediated anti-tumor cytotoxic response. By specifically targeting the activity levels of the ERAP1 variant expressed, we can adopt a personalized approach that maximizes the potential production of neoantigens, crucial for activating an anti-tumor immune response. We CRISPR knocked out the ERAP1 gene in the CT26 cell line and assessed the MHC I kinetics and stability by investigating the dissociation of pMHC complexes at the cell surface, using a Brefeldin-A decay assay and an acid-stripping test compared to wild-type. The assessment of MHC I assembly and cell surface expression kinetics showed higher MHC I in the ERAP1 KO cell line, highlighting that the lack of ERAP1 translated into a faster recovery time of peptide/MHC complexes at the cell surface. After assessing the kinetics, we re-expressed different human ERAP1 allotypes in CT26 ERAP1KO cell line through retroviral transduction and characterized MHC I expression levels through flow cytometry. Interestingly, MHC I expression levels varied across the transduced samples, with specific variants showing much higher expression levels indicating more peptide availability for loading onto the MHC molecules. Immunopeptidomic analysis comparing the WT, ERAP1 KO and the CT26 human ERAP1 transduced cell lines, showed distinct subsets of neoantigens presented in the KO cell line. ERAP1 plays a significant role in the assembly and recovery of peptide/MHC complexes. The reintroduction of different ERAP1 allelic variants greatly alters MHC I expression levels suggesting the formation of new peptide-MHC complexes responsible for the increase in MHC I expression. Modulation of ERAP1 activity significantly alters the presented peptide repertoire , uncovering neoantigens which are potentially immunogenic. Citation Format: Shami Alvarez Mourid, Edward James, Dario Guglietta, Emma Reeves. Effects of modulation of ERAP1 activity in antigen processing and presentation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB367.

ERAP1 Controls the Autoimmune Response against Melanocytes in Psoriasis by Generating the Melanocyte Autoantigen and Regulating Its Amount for HLA-C*06:02 Presentation

ERAP1 and ERAP2 Gene Variants as Potential Clinical Biomarkers of Anti-IL-17A Response in Psoriasis Vulgaris

Melanocyte antigen triggers autoimmunity in human psoriasis

Polymorphisms in ERAP1 gene are associated with psoriasis

Human Leukocyte Antigen-Class I Alleles and the Autoreactive T Cell Response in Psoriasis Pathogenesis

Associations between ERAP1 polymorphisms and ankylosing spondylitis susceptibility: An updated meta-analysis.

ERAP1: a potential therapeutic target for a myriad of diseases

Multiple environmental antigens may trigger autoimmunity in psoriasis through T-cell receptor polyspecificity

Multifactor Dimensionality Reduction Reveals the Effect of Interaction Between ERAP1 and IFIH1 Polymorphisms in Psoriasis Susceptibility Genes.

Brief Report: Functional Interaction of Endoplasmic Reticulum Aminopeptidase 2 and HLA–B27 Activates the Unfolded Protein Response

Endoplasmic reticulum aminopeptidase 2 regulates CD4+ T cells pyroptosis in rheumatoid arthritis

Mice expressing human ERAP1 variants associated with ankylosing spondylitis have altered T-cell repertoires and NK cell functions, as well as increased in utero and perinatal mortality

Abstract LB367: Effects of modulation of ERAP1 activity in antigen processing and presentation

Synergy of endoplasmic reticulum aminopeptidase 1 and 2 (ERAP1 and ERAP2) polymorphisms in atopic dermatitis: Effects on disease prevalence

Role of Aryl Hydrocarbon Receptor Activation and Autophagy in Psoriasis-Related Inflammation

Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes

RAS‐association Domain Family 1A Regulates the Abnormal Cell Proliferation in Psoriasis Via Inhibition of Yes‐associated Protein

Functional ERAP1 Variants Distinctively Associate with Ankylosing Spondylitis Susceptibility under the Influence of HLA-B27 in Taiwanese

Possible Role of Endoplasmatic Reticulum Stress in Psoriasis Vulgaris

A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1

ERAP1 activity modulates the immunopeptidome but also affects the proteome, metabolism and stress responses in cancer cells